Conventional white light imaging-assisted transurethral resection of bladder tumor (TURBT) vs IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: Trial protocol and 18 months results
World Journal of Urology — de la Rosette J, Martov A, Hurle R, et al. | November 09, 2021
In non-muscle-invasive bladder cancer (NMIBC) cases, overall recurrence rates did not differ between IMAGE1S and white light (WL) assistance 18-mo post-transurethral resection of bladder tumor (TURBT). However, a considerable decrease in the probability of disease recurrence in primary, low/intermediate risk cases was achieved with IMAGE1S-assisted TURBT.
A single-blinded randomized controlled trial in which 689 patients with primary and recurrent NMIBC were randomized 1:1 to WL-assisted (n = 354) or IMAGE1S-assisted (n = 335) TURBT.
The 18-mo follow-up was completed by 60 and 65 patients, respectively, with recurrence rates of 31.0% and 25.4%, respectively.
At 18-mo, significantly higher recurrence rates in patients with primary, low-/intermediate-risk tumors were observed in the WL group vs the IMAGE1S group (31.9% and 22.3%, respectively).
Both treatment groups showed a comparable frequency and severity of adverse events.
No difference in immediate and adjuvant intravesical instillation therapy was identified between the groups.
Read the full article on World Journal of Urology